Mode
Text Size
Log in / Sign up
Phase 4 N=77 Randomized Triple-blind Treatment

Dexmedetomidine Versus Propofol in Vitreoretinal Surgery

Retinal Detachment

Enrolled (actual)
77
Serious AEs
1.3%
Results posted
Aug 2017
Primary outcome: Primary: Adequate Sedation Via Bispectral Index Score (BIS)and University of Michigan Sedation Scale (UMSS) — 84.8; 88; .90; .94 units on a scale — p=0.04

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Dexmedetomidine infusion (Drug); propofol (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Rutgers, The State University of New Jersey
Primary completion
Mar 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Adequate Sedation Via Bispectral Index Score (BIS)and University of Michigan Sedation Scale (UMSS)
84.8; 88; .90; .94 0.04 sig
PRIMARY
Intraoperative Hemodynamic Stability
124.9; 114.6; 73.6; 66.2
PRIMARY
Intraoperative Respiratory Stability
17; 12
PRIMARY
Intraoperative Heart Rate Stability
71; 64
SECONDARY
Time to Achieve "Street Fitness"
81; 85
SECONDARY
Surgeon Satisfaction for Adequate Sedation
4.62; 4.97
SECONDARY
Surgeon Satisfaction for Adequate Sedation at Completion of Procedure
4.77; 4.89
SECONDARY
Patient Satisfaction
4.61; 4.43
SECONDARY
Post Operative Hemodynamic Stability
124.9; 114.6; 73.6; 66.2
SECONDARY
Hemodynamic Stability Post Operatively in PACU
74.1; 72

Summary

The investigators would like to determine if using Dexmedetomidine alone or in a reduced dose can prevent or reduce the incidence of adverse effects, while providing adequate sedation, and respiratory stability as compared to propofol.

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists rating of I-III
  • good renal and liver function

Exclusion Criteria

  • renal and hepatic insufficiency
  • uncontrolled diabetes
  • uncontrolled hypertension
  • severe cardiac disease Class III or IV
  • heart blocks
  • chronic use of sedatives, narcotics, alcohol or illicit drugs
  • allergy to either propofol or dexmedetomidine
  • pregnancy or inability to tolerate technique of the study drugs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01001429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search